Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer

International Journal of Pharmaceutics

Volumn 392, Issue 1-2, 2010, Pages 156-163

  Xie, Yumei ^a   Aillon, Kristin L ^a   Cai, Shuang ^a   Christian, Jason M ^b   Davies, Neal M ^c   Berkland, Cory J ^a,b   Forrest, M Laird ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Kansas   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cisplatin; Hyaluronan; Lung chemotherapeutics; Pharmacokinetics; Pulmonary delivery

Indexed keywords

CISPLATIN; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BRAIN; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RELEASE; DRUG TISSUE LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY; LUNG CANCER; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG CARRIERS; FEMALE; HYALURONIC ACID; INJECTIONS, INTRAVENOUS; INTUBATION, INTRATRACHEAL; LUNG; LUNG NEOPLASMS; LYMPH NODES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTROPHOTOMETRY, ATOMIC; TISSUE DISTRIBUTION;

EID: 77952742066     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.058     Document Type: Article

References (28)

1. Banzato A., Bobisse S., Rondina M., Renier D., Bettella F., Esposito G., Quintieri L., Melendez-Alafort L., Mazzi U., Zanovello P., Rosato A. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 2008, 14:3598-3606.
2. Brown D.B., Cai S.R., Fundakowski C.E., Zamboni W.C., Strychor S., McLeod H.L. Pharmacokinetics after endovascular lung perfusion with cisplatin. J. Vasc. Interv. Radiol. 2006, 17:883-888.
3. Brown T.J. The development of hyaluronan as a drug transporter and excipient for chemotherapeutic drugs. Curr. Pharm. Biotechnol. 2008, 9:253-260.
4. Cafaggi S., Russo E., Stefani R., Leardi R., Caviglioli G., Parodi B., Bignardi G., De Totero D., Aiello C., Viale M. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex. J. Control. Release 2007, 121:110-123.
5. Cai S., Xie Y.M., Bagby T.R., Cohen M.S., Forrest M.L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J. Surg. Res. 2008, 147:247-252.
6. Carrick S., Ghersi D., Wilcken N., Simes J. Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst. Rev. 2004, CD003374.
7. Chen J.T., Hasumi K. Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry. Gan To Kagaku Ryoho 1995, 22:653-657.
8. Chu G. Cellular-responses to cisplatin-the roles of DNA-binding proteins and DNA-repair. J. Biol. Chem. 1994, 269:787-790.
9. Devarajan P., Tarabishi R., Mishra J., Ma Q., Kourvetaris A., Vougiouka M., Boulikas T. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res. 2004, 24:2193-2200.
10. Fraser J.R., Laurent T.C. Turnover and metabolism of hyaluronan. Ciba Found. Symp. 1989, 143:41-53. (discussion 53-49, 281-285).
11. Gagnadoux F., Hureaux J., Vecellio L., Urban T., Le Pape A., Valo I., Montharu J., Leblond V., Boisdron-Celle M., Lerondel S., Majoral C., Diot P., Racineux J.L., Lemarie E. Aerosolized chemotherapy. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:61-69.
12. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2004, 22:3852-3859.
13. Ihde D.C., Mulshine J.L., Kramer B.S., Steinberg S.M., Linnoila R.I., Gazdar A.F., Edison M., Phelps R.M., Lesar M., Phares J.C., Grayson J., Minna J.D., Johnson B.E. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung-cancer. J. Clin. Oncol. 1994, 12:2022-2034.
14. Ikeda K., Terashima M., Kawamura H., Takiyama I., Koeda K., Takagane A., Sato N., Ishida K., Iwaya T., Maesawa C., Yoshinari H., Saito K. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn. J. Clin. Oncol. 1998, 28:168-175.
15. Jeong Y.I., Kim S.T., Jin S.G., Ryu H.H., Jin Y.H., Jung T.Y., Kim I.Y., Jung S. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J. Pharm. Sci. 2008, 97:1268-1276.
16. Junior A.D.C., Vieira F.P., De Melo V.J., Lopes M.T.P., Silveira J.N., Ramaldes G.A., Garnier-Suillerot A., Pereira-Maia E.C., De Oliveira M.C. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz. J. Med. Biol. Res. 2007, 40:1149-1157.
17. Kim E.S., Lu C., Khuri F.R., Tonda M., Glisson B.S., Liu D., Jung M., Hong W.K., Herbst R.S. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001, 34:427-432.
18. Kurihara N., Kubota T., Hoshiya Y., Otani Y., Ando N., Kumai K., Kitajima M. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J. Surg. Oncol. 1996, 62:135-138.
19. Launay-Vacher V., Rey J.B., Isnard-Bagnis C., Deray G., Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother. Pharmacol. 2008, 61:903-909.
20. Nishiyama N., Kataoka K. Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core. J. Control. Release 2001, 74:83-94.
21. Nishiyama N., Okazaki S., Cabral H., Miyamoto M., Kato Y., Sugiyama Y., Nishio K., Matsumura Y., Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003, 63:8977-8983.
22. Perng R.P., Chen Y.M., MingLiu J., Tsai C.M., Lin W.C., Yang K.Y., WhangPeng J. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J. Clin. Oncol. 1997, 15:2097-2102.
23. Rabik C.A., Fishel M.L., Holleran J.L., Kasza K., Kelley M.R., Egorin M.J., Dolan M.E. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O-6-benzylguanine involves endoplasmic reticulum stress. J. Pharmacol. Exp. Ther. 2008, 327:442-452.
24. Selting K., Waldrep J.C., Reinero C., Branson K., Gustafson D., Kim D.Y., Henry C., Owen N., Madsen R., Dhand R. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe (R) Intracorporeal Nebulization Catheter. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:255-268.
25. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
26. Uchino H., Matsumura Y., Negishi T., Koizumi F., Hayashi T., Honda T., Nishiyama N., Kataoka K., Naito S., Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br. J. Cancer 2005, 93:678-687.
27. Ye H., Jin L., Hu R., Yi Z., Li J., Wu Y., Xi X., Wu Z. Poly(gamma, l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 2006, 27:5958-5965.
28. Zatloukal P., Petruzelka L., Zemanova M., Kolek V., Skrickova J., Pesek M., Fojtu H., Grygarkova I., Sixtova D., Roubec J., Horenkova E., Havel L., Prusa P., Novakova L., Skacel T., Kuta M. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003, 41:321-331.